Elicio Therapeutics, Inc. ELTX
1.84
(0.04)
(2.13%)
as of 25 Sep
- Market cap
- $53.4M
- P/E
- 0.0×
Follow ELTX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
— | 89.87 | 89.87 | 89.87 | 2.89 | 0.10 | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
— | 12.57 | 12.57 | 12.57 | (5.70) | (0.38) | — | — | — |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | — | — | — |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | — | — | — |
EV/Sales |
— | 78.16 | 78.16 | 78.16 | (0.20) | (0.05) | — | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.16 | 0.06 | — | — | — |
EV/Operating CF |
— | (9.84) | (9.84) | (9.84) | 0.11 | 0.06 | — | — | — |
EV/FCF |
— | (9.82) | (9.82) | (9.82) | 0.11 | 0.06 | — | — | — |
Quick Ratio |
— | 3.48 | 0.23 | 0.32 | 7.93 | 1.18 | 1.40 | 1.63 | 2.29 |
Current Ratio |
— | 3.49 | 0.23 | 0.39 | 8.08 | 1.56 | 1.68 | 1.80 | 2.38 |
Net Debt/EBITDA |
— | 1.78 | (0.14) | 0.72 | 2.39 | 0.29 | 0.39 | (0.03) | 0.25 |
Debt/Assets |
0.00% | 0.00% | 90.68% | 1.89% | 1.17% | 5.42% | 0.00% | 71.10% | 36.37% |
Debt/Equity |
— | 0.00 | (0.58) | (0.01) | 0.01 | 0.14 | 0.00 | (1.77) | 5.75 |
Asset Turnover |
— | 0.30 | 0.08 | 0.10 | 0.39 | 0.04 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.32 | 0.60 | 0.29 | 0.96 | 0.79 | 0.93 | 0.71 | 0.93 |
Capex/Depreciation |
— | 0.00 | (0.49) | 0.00 | (0.14) | (0.62) | (0.03) | (0.07) | (0.01) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (15,387.69%) | (25,020.31%) | 146.94% | 1,220.60% | 273.36% | 77.55% | (170,157.38%) | 817.92% | |
| — | (187.81%) | (211.13%) | (270.48%) | (75.87%) | (47.34%) | (141.32%) | (187.61%) | (146.45%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | (632.00%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (136.33%) | 200.68% | 123.25% | (67.88%) | (564.61%) | (481.46%) | (537.64%) | (344.22%) |
Average Days of Receivables |
— | 9.69 | 108.00 | 0.00 | 10.39 | 48.38 | — | — | — |
Research and Development Expense of Revenue |
— | 312.78% | 2,006.52% | 1,353.37% | 172.00% | 786.74% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 133.80% | 645.66% | 624.51% | 65.30% | 244.68% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 224.34% | 163.75% | 42.53% | 25.16% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.37) | (0.37) | (0.37) | 0.93 | (1.10) | — | — | — |
Graham Number |
— | 0.00 | 0.00 | 268.96 | 0.00 | 619.14 | — | — | — |
Earnings Yield |
— | (31.76%) | (31.76%) | (31.76%) | (72.07%) | (604.43%) | — | — | — |
Free Cash Flow Yield |
— | (8.86%) | (8.86%) | (8.86%) | (64.74%) | (829.93%) | — | — | — |
Revenue per Share |
— | 1.37 | 1.03 | 1.95 | 10.02 | 7.28 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (2.72) | (17.03) | (15.50) | (18.64) | (70.19) | (6.47) | (3.04) | (2.41) |
Capex per Share |
— | 0.00 | (0.17) | (0.03) | (0.14) | (2.07) | (0.01) | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (2.72) | (17.20) | (15.53) | (18.77) | (72.26) | (6.47) | (3.04) | (2.41) |
Cash per Share |
— | 8.66 | 3.86 | 23.44 | 31.42 | 24.67 | 2.69 | 1.54 | 1.21 |
Shareholders Equity per Share |
— | 6.42 | (12.88) | (61.27) | 28.86 | 28.21 | 2.25 | (0.93) | 0.11 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 6.42 | (12.88) | (61.27) | 28.86 | 28.21 | 2.25 | (0.93) | 0.11 |
Free Cash Flow |
— | (8.02) | (24.83) | (22.93) | (53.02) | (22.83) | (32.73) | (37.15) | (36.97) |
Working Capital |
— | 18.32 | (20.47) | (65.15) | 79.95 | 3.85 | 6.59 | 9.17 | 11.20 |
Capital Expenditures |
— | — | (0.24) | (0.04) | (0.38) | (0.65) | (0.03) | (0.08) | (0.02) |
Net Current Asset Value |
— | 17.96 | (24.37) | (95.50) | 76.24 | (3.03) | 0.58 | (18.80) | (4.91) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.15 | 0.06 | — | — | — |
Capex to Sales |
— | 0.00 | 0.16 | 0.01 | 0.01 | 0.28 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | (620.63%) | (2,734.23%) | (2,781.49%) | (192.76%) | (1,225.90%) | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.12 | 2.37 | 53.13 | 5.95 | 0.92 | 1.63 | 2.59 | 4.56 |
Cash ROIC |
— | (18.09%) | 1,108.54% | 41.94% | (30.98%) | (130.02%) | (133.70%) | (136.46%) | (125.81%) |
Accounts Receivable Turnover |
— | 14.73 | 5.44 | 0.00 | 45.44 | 4.14 | — | — | — |
Accounts Payable Turnover |
— | 0.06 | 0.11 | 0.14 | 0.08 | 0.26 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 515.63 | 6,409.74 | 1,710.90 | 3,970.32 | 1,033.12 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.27 | 0.27 | — | 0.62 | 0.56 | — | — | — |
Average Payables |
— | 5.89 | 5.89 | 8.41 | 5.14 | 3.76 | 3.59 | 2.70 | 0.86 |
Average Assets |
— | 13.31 | 19.26 | 29.62 | 71.93 | 59.59 | 24.91 | 27.66 | 27.02 |
Average Common Equity |
— | 0.16 | 0.16 | (54.52) | (4.47) | (10.32) | (45.39) | 0.03 | (4.84) |
Columns are period end dates